TAO Synergies (TAOX) Accounts Payables (2019 - 2026)
TAO Synergies' (TAOX) quarterly Accounts Payables came in at $899175.0 in Q2 2026, little changed on a YoY basis from $898153.0 in Q2 2025, and down 4.98% quarter-over-quarter from $946327.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Accounts Payables (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Accounts Payables for 8 consecutive years, with $899175.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Accounts Payables changed 0.11% year-over-year to $899175.0; the trailing twelve-month figure through Jun 2026 stood at $899175.0 (changed 0.11% YoY), and the FY2025 full-year result was $1.2 million, up 270.43% from the prior year.
- Accounts Payables retreated to $899175.0 in Q2 2026 per TAOX's latest filing, from $946327.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $1.2 million in Q4 2025 and bottomed at $114181.0 in Q1 2025.
- Historically, Accounts Payables has averaged $532243.9 across 5 years, with a median of $441890.0 in 2023.
- The sharpest annual moves came in 2022 and 2026: Accounts Payables sank 56.67% in 2022, then soared 728.8% in 2026.
- Over 5 years, Accounts Payables stood at $660206.0 in 2022, then slumped by 32.65% to $444633.0 in 2023, then dropped by 28.64% to $317287.0 in 2024, then surged by 270.43% to $1.2 million in 2025, then slipped by 23.5% to $899175.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $899175.0, $946327.0, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | 25.08 Mn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | 899,175.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 899,175.00 |
| Mar 31, 2026 | 946,327.00 |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 949,650.00 |
| Jun 30, 2025 | 898,153.00 |
| Mar 31, 2025 | 114,181.00 |
| Dec 31, 2024 | 317,287.00 |
| Sep 30, 2024 | 286,350.00 |
| Jun 30, 2024 | 475,330.00 |
| Mar 31, 2024 | 238,905.00 |
| Dec 31, 2023 | 444,633.00 |
| Sep 30, 2023 | 214,218.00 |
| Jun 30, 2023 | 439,147.00 |
| Mar 31, 2023 | 355,901.00 |
| Dec 31, 2022 | 660,206.00 |
| Sep 30, 2022 | 483,390.00 |
| Jun 30, 2022 | 280,865.00 |
| Mar 31, 2022 | 401,349.00 |
| Dec 31, 2021 | 1.30 Mn |
| Sep 30, 2021 | 935,376.00 |